Coronary stents and non-cardiac surgery: to bridge or not to bridge?

Editorial Focus on Capodanno et al. Thromb Haemost 2015; 114: 423–431.

• References

• 1 Hamm CW, Bassand JP, Agewall S. et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). EurHeart J 2011; 32: 2999-3054.
• 2 Steg PG, James SK, Atar D. et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). EurHeart J 2012; 33: 2569-2619.
• 3 Windecker S, Kolh P, Alfonso F. et al. 2014 ESC/ EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). EurHeart J 2014; 35: 2541-2619.
• 4 Collet JP, Montalescot G, Blanchet B. et al. Impact of prior use or recent withdrawal of oral antiplatelet agents on acute coronary syndromes. Circulation 2004; 110: 2361-2367.
• 5 Ferreira-Gonzalez I, Marsal JR, Ribera A. et al. Double antiplatelet therapy after drug-eluting stent implantation: risk associated with discontinuation within the first year. J Am Coll Cardiol 2012; 60: 1333-1339.
• 6 Berger PB, Kleiman NS, Pencina MJ. et al. Frequency of major noncardiac surgery and subsequent adverse events in the year after drug-eluting stent placement results from the EVENT (Evaluation of Drug-Eluting Stents and Ischemic Events) Registry. JACC Cardiovasc Interv 2010; 03: 920-927.
• 7 Rossini R, Capodanno D, Lettieri C. et al. Prevalence, predictors, and long-term prognosis of premature discontinuation of oral antiplatelet therapy after drug eluting stent implantation. Am J Cardiol 2011; 107: 186-194.
• 8 Rossini R, Musumeci G, Capodanno D. et al. Peri-operative management of oral antiplatelet therapy and clinical outcomes in coronary stent patients undergoing surgery. Results of a multicentre registry. Thromb Haemost 2015; 113: 272-282.
• 9 Devereaux PJ, Mrkobrada M, Sessler DI. et al. Aspirin in patients undergoing noncardiac surgery. N Engl J Med 2014; 370: 1494-1503.
• 10 Hansson EC, Rexius H, Dellborg M. et al. Coronary artery bypass grafting-related bleeding complications in real-life acute coronary syndrome patients treated with clopidogrel or ticagrelor. Eur J Cardiothorac Surg 2014; 46: 699-705.
• 11 Grove EL, Hossain R, Storey RF. Platelet function testing and prediction of procedural bleeding risk. Thromb Haemost 2013; 109: 817-824.
• 12 Kristensen SD, Knuuti J, Saraste A. et al. 2014 ESC/ ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). Eur Heart J 2014; 35: 2383-2431.
• 13 Mehran R, Baber U, Steg PG. et al. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet 2013; 382: 1714-1722.
• 14 Parolari A, Mussoni L, Frigerio M. et al. Increased prothrombotic state lasting as long as one month after on-pump and off-pump coronary surgery. J Thorac Cardiovasc Surg 2005; 130: 303-308.
• 15 Modrau IS, Wurtz M, Kristensen SD. et al. Reduced Effect of Aspirin and Clopidogrel Following Hybrid Coronary Revascularization. Clin Appl Thromb Hemost. 2015 Epub ahead of print.
• 16 De Luca G, Dirksen MT, Spaulding C. et al. Time course, predictors and clinical implications of stent thrombosis following primary angioplasty. Insights from the DESERT cooperation. Thromb Haemost 2013; 110: 826-833.
• 17 Armstrong EJ, Sab S, Singh GD. et al. Predictors and outcomes of recurrent stent thrombosis: results from a multicenter registry. JACC Cardiovasc Interv 2014; 07: 1105-1113.
• 18 Capodanno D, Angiolillo DJ. Management of anti-platelet therapy in patients with coronary artery disease requiring cardiac and noncardiac surgery. Circulation 2013; 128: 2785-2798.
• 19 Kristensen SD, Wurtz M, Grove EL. et al. Contemporary use of glycoprotein IIb/IIIa inhibitors. Thromb Haemost 2012; 107: 215-224.
• 20 Savonitto S, Caracciolo M, Cattaneo M. et al. Management of patients with recently implanted coronary stents on dual antiplatelet therapy who need to undergo major surgery. J Thromb Haemost 2011; 09: 2133-2142.
• 21 Rassi AN, Blackstone E, Militello MA. et al. Safety of “bridging” with eptifibatide for patients with coronary stents before cardiac and non-cardiac surgery. Am J Cardiol 2012; 110: 485-490.
• 22 Warshauer J, Patel VG, Christopoulos G. et al. Outcomes of preoperative bridging therapy for patients undergoing surgery after coronary stent implantation: a weighted meta-analysis of 280 patients from eight studies. Catheter Cardiovasc Interv 2015; 85: 25-31.
• 23 Angiolillo DJ, Firstenberg MS, Price MJ. et al. Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. J Am Med Assoc 2012; 307: 265-274.
• 24 Omran H, Bauersachs R, Rubenacker S. et al. The HAS-BLED score predicts bleedings during bridging of chronic oral anticoagulation. Results from the national multicentre BNK Online bRiDging REgistRy (BORDER). Thromb Haemost 2012; 108: 65-73.
• 25 Capodanno D, Musumeci G, Lettieri C. et al. Impact of Bridging with Perioperative Low-Molecular Weight Heparin on Cardiac and Bleeding Outcomes of Stented Patients Undergoing Non-Cardiac Surgery. Thromb Haemost 2015; 114: 423-431.
• 26 Limantoro I, Pisters R. Peri-procedural antithrombotic bridging and the assessment of the associated risk of major bleeding. Thromb Haemost 2012; 108: 9-10.
• 27 Spyropoulos AC. Pro: “Bridging anticoagulation is needed during warfarin interruption in patients who require elective surgery”. Thromb Haemost 2012; 108: 213-216.
• 28 Douketis JD. Contra: “Bridging anticoagulation is needed during warfarin interruption when patients require elective surgery”. Thromb Haemost 2012; 108: 210-212.
• 29 Douketis JD, Healey JS, Brueckmann M. et al. Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure. Substudy of the RE-LY trial. Thromb Haemost 2015; 113: 625-632.